Pembrolizumab: bei höherer PD-L1-Expression hoch effektiv

Mok TSK et al. Lancet. 2019;393(10183):1819–30
Article CAS PubMed Google Scholar
Ramos-Esquivel A et al. ESMO Open. 2017;2(3):e000236
Article PubMed PubMed Central Google Scholar
Reck M et al. N Engl J Med. 2016;375(19):1823–33
Article CAS PubMed Google Scholar
Reck M et al. J Clin Oncol. 2019;37(7):537–46
Article CAS PubMed Google Scholar
Carbone DP et al. N Engl J Med. 2017;376(25):2415–26
Article CAS PubMed PubMed Central Google Scholar

Mok TSK et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183): 1819–30
Article CAS PubMed Google Scholar

Author information

Authors

Andreas Schalhorn
View author publications
You can also search for this author in PubMed Google Scholar

Correspondence to Andreas Schalhorn.

Schalhorn, A. Pembrolizumab: bei höherer PD-L1-Expression hoch effektiv. Info Onkol. 22, 36–38 (2019). https://doi.org/10.1007/s15004-019-6652-4

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.